—
Summary‘Esophageal Cancer - Pipeline Review, H2 2016’, provides an overview of the Esophageal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.
Request a sample report @ https://www.wiseguyreports.com/sample-request/693289-esophageal-cancer-pipeline-review-h2-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
- The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Esophageal Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693289-esophageal-cancer-pipeline-review-h2-2016
Key points in table of content
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Esophageal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Esophageal Cancer - Overview 11
Pipeline Products for Esophageal Cancer - Comparative Analysis 12
Esophageal Cancer - Therapeutics under Development by Companies 13
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Esophageal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Esophageal Cancer - Products under Development by Companies 21
Esophageal Cancer - Products under Investigation by Universities/Institutes 26
Esophageal Cancer - Companies Involved in Therapeutics Development 27
Adaptimmune Therapeutics Plc 27
Advaxis, Inc. 28
Advenchen Laboratories, LLC 29
Almac Discovery Limited 30
Amgen Inc. 31
ArQule, Inc. 32
Array BioPharma Inc. 33
Aslan Pharmaceuticals Pte. Ltd. 34
ATLAB Pharma SAS 35
Bayer AG 36
Betta Pharmaceuticals Co. Ltd. 37
Boehringer Ingelheim GmbH 38
Celgene Corporation 39
Celldex Therapeutics, Inc. 40
Cellectar Biosciences, Inc. 41
Cerulean Pharma, Inc. 42
Cyclacel Pharmaceuticals, Inc. 43
F. Hoffmann-La Roche Ltd. 44
Genmab A/S 45
GlaxoSmithKline Plc 46
Glycotope GmbH 47
Hutchison MediPharma Limited 48
Ignyta, Inc. 49
ImmunoFrontier, Inc. 50
Immunomedics, Inc. 51
Johnson & Johnson 52
Komipharm International Co., Ltd. 53
MacroGenics, Inc. 54
MaxiVAX SA 55
Mebiopharm Co., Ltd. 56
MedImmune, LLC 57
Merck & Co., Inc. 58
Mirna Therapeutics, Inc. 59
Novartis AG 60
Omeros Corporation 61
Omnitura Therapeutics Inc. 62
Oncolys BioPharma Inc 63
OncoMed Pharmaceuticals, Inc. 64
Ono Pharmaceutical Co., Ltd. 65
Pfizer Inc. 66
Proteo, Inc. 67
Puma Biotechnology, Inc. 68
Rhizen Pharmaceuticals S.A. 69
Shionogi & Co., Ltd. 70
Spectrum Pharmaceuticals, Inc. 71
Symphogen A/S 72
Taiho Pharmaceutical Co., Ltd. 73
Taiwan Liposome Company, Ltd. 74
Takara Bio Inc. 75
Transgene Biotek Limited 76
VioQuest Pharmaceuticals, Inc. 77
XuanZhu Pharma Co., Ltd. 78
Esophageal Cancer - Therapeutics Assessment 79
Assessment by Monotherapy Products 79
Assessment by Combination Products 80
Assessment by Target 81
Assessment by Mechanism of Action 86
Assessment by Route of Administration 91
Assessment by Molecule Type 93
Drug Profiles 95
(tipiracil hydrochloride + trifluridine) - Drug Profile 95
1-BB1 - Drug Profile 101
ADXS-HER2 - Drug Profile 102
afatinib dimaleate - Drug Profile 106
AL-3818 - Drug Profile 117
ALM-301 - Drug Profile 119
alpelisib - Drug Profile 120
AMG-337 - Drug Profile 123
apatinib - Drug Profile 125
atezolizumab - Drug Profile 128
ATL-101 - Drug Profile 141
Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693289
Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WiseGuy Research Consultant Pvt Ltd
Address: WISE GUY RESEARCH CONSULTANTS PVT LTD Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India Ph: +91 841 198 5042 info@wiseguyreports.com
Phone: +1-646-845-9349 (US) +44 208 133 9349 (UK)t
Website: https://www.wiseguyreports.com
Release ID: 140105
Google
RSS